H.C. Wainwright Rates Palvella Therapeutics as a Buy
H.C. Wainwright initiates coverage on Palvella Therapeutics, citing growth potential of its lead biotech product. Explore its promising sales prospects.
Topic
biotech
A collection of 25 issues
H.C. Wainwright Upgrades Rapt Therapeutics on New Licensing Deal
Rapt Therapeutics receives a boost as H.C. Wainwright upgrades it to Buy following a new licensing agreement for an anti-immunoglobulin E monoclonal antibody.
Scotiabank Rates Thermo Fisher, Danaher, Waters as Sector Perform
Scotiabank initiates coverage on Thermo Fisher Scientific, Danaher, and Waters Corporation with Sector Perform ratings amid market uncertainties in biotech and life sciences.
William Blair Downgrades Applied Therapeutics to Market Perform
William Blair downgrades Applied Therapeutics (APLT) to Market Perform amid management turnover and uncertain revenue prospects.
H.C. Wainwright Upgrades Aclaris Therapeutics to Buy
H.C. Wainwright upgrades Aclaris Therapeutics (ACRS) to Buy, setting a $20 price target following an exclusive license deal with Biosion. Explore investment opportunities in biotech growth.